VICTORIA, BC, July 20, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback